Bibliometric analysis and description of research trends in the treatment of psoriasis with biologic agents in the past two decades (2004–2023)

References

• McInnes IB, Gravallese EM. Immune-mediated inflammatory disease therapeutics: past, present and future. Nat Rev Immunol. 2021;21(10):1–11. doi: 10.1038/s41577-021-00603-1.
   PubMed Web of Science ®Google Scholar
• Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol. 2002;46(1):1–26. doi: 10.1067/mjd.2002.120568.
   PubMed Web of Science ®Google Scholar
• Chamian F, Lin SL, Lee E, et al. Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (tem) and relative preservation of Central memory T cells (tcm) in psoriasis. J Transl Med. 2007;5(1):27. doi: 10.1186/1479-5876-5-27.
   PubMedGoogle Scholar
• Haider AS, Cohen J, Fei J, et al. Insights into gene modulation by therapeutic TNF and IFNgamma antibodies: TNF regulates IFNgamma production by T cells and TNF-regulated genes linked to psoriasis transcriptome. J Invest Dermatol. 2008;128(3):655–666. doi: 10.1038/sj.jid.5701064.
   PubMed Web of Science ®Google Scholar
• Schlapbach C, Conrad C. TYK-ing all the boxes in psoriasis. J Allergy Clin Immunol. 2022;149(6):1936–1939. doi: 10.1016/j.jaci.2022.03.014.
   PubMed Web of Science ®Google Scholar
• Chen C, Song M. Visualizing a field of research: a methodology of systematic scientometric reviews. PLoS One. 2019;14(10):e0223994. doi: 10.1371/journal.pone.0223994.
   PubMed Web of Science ®Google Scholar
• Kokol P, Blažun Vošner H, Završnik J. Application of bibliometrics in medicine: a historical bibliometrics analysis. Health Info Libr J. 2021;38(2):125–138. doi: 10.1111/hir.12295.
   PubMed Web of Science ®Google Scholar
• Chen CH, Chien TW, Yu-Chieh Ho S, et al. Predicting article citations using data from 100 top-cited publications in the field of psoriasis vulgaris and biological agents (PVBA) since 1991: a bibliometric analysis. Medicine (Baltimore). 2022;101(30):e29396. doi: 10.1097/MD.0000000000029396.
   PubMed Web of Science ®Google Scholar
• Langley RG, Elewski BE, Lebwohl M, FIXTURE Study Group., et al. Secukinumab in plaque psoriasis–results of two phase 3 trials. N Engl J Med. 2014;371(4):326–338. doi: 10.1056/NEJMoa1314258.
   PubMed Web of Science ®Google Scholar
• Parisi R, Iskandar IYK, Kontopantelis E, and Global Psoriasis Atlas., et al. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369:m1590. doi: 10.1136/bmj.m1590.
   PubMed Web of Science ®Google Scholar
• Shao K, Hooper J, Feng H. Racial and ethnic health disparities in dermatology in the United States. Part 2: disease-specific epidemiology, characteristics, management, and outcomes. J Am Acad Dermatol. 2022;87(4):733–744. doi: 10.1016/j.jaad.2021.12.062.
   PubMed Web of Science ®Google Scholar
• Narla S, Heath CR, Alexis A, et al. Racial disparities in dermatology. Arch Dermatol Res. 2023;315(5):1215–1223. doi: 10.1007/s00403-022-02507-z.
   PubMed Web of Science ®Google Scholar
• Molloy ES, Calabrese LH. Therapy: Targeted but not trouble-free: efalizumab and PML. Nat Rev Rheumatol. 2009;5(8):418–419. doi: 10.1038/nrrheum.2009.142.
   PubMed Web of Science ®Google Scholar
• Erichsen CY, Jensen P, Kofoed K. Biologic therapies targeting the interleukin (IL)-23/IL-17 immune axis for the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2020;34(1):30–38. doi: 10.1111/jdv.15879.
   PubMed Web of Science ®Google Scholar
• Bellinato F, Gisondi P, Girolomoni G. Latest advances for the treatment of chronic plaque psoriasis with biologics and oral small molecules. Biologics. 2021;15:247–253. doi: 10.2147/BTT.S290309.
   PubMed Web of Science ®Google Scholar
• Strychalski ML, Brown HS, Bishop SC. Cytokine modulators in plaque Psoriasis - A review of current and prospective biologic therapeutic approaches. JAAD Int. 2022;9:82–91. doi: 10.1016/j.jdin.2022.08.008.
   PubMedGoogle Scholar
• Guo J, Zhang H, Lin W, et al. Signaling pathways and targeted therapies for psoriasis. Signal Transduct Target Ther. 2023;8(1):437. doi: 10.1038/s41392-023-01655-6.
   PubMed Web of Science ®Google Scholar
• Damiani G, Allocco F, Malagoli P, Young Dermatologists Italian Network. COVID-19 vaccination and patients with psoriasis under biologics: real-life evidence on safety and effectiveness from italian vaccinated healthcare workers. Clin Exp Dermatol. 2021;46(6):1106–1108. doi: 10.1111/ced.14631.
   PubMed Web of Science ®Google Scholar
• Campanati A, Diotallevi F, Martina E, et al. Treatment of moderate to severe psoriasis during the COVID-19 pandemic: lessons learned and opportunities. J Clin Med. 2022;11(9):2422. doi: 10.3390/jcm11092422.
   PubMed Web of Science ®Google Scholar
• Piccolo V, Russo T, Mazzatenta C, et al. COVID vaccine-induced pustular psoriasis in patients with previous plaque type psoriasis. J Eur Acad Dermatol Venereol. 2022;36(5):e330–e332. doi: 10.1111/jdv.17918.
   PubMed Web of Science ®Google Scholar
• Iversen L, Eidsmo L, Austad J, et al. Secukinumab treatment in new-onset psoriasis: aiming to understand the potential for disease modification - rationale and design of the randomized, multicenter STEPIn study. J Eur Acad Dermatol Venereol. 2018;32(11):1930–1939. doi: 10.1111/jdv.14979.
   PubMed Web of Science ®Google Scholar
• Li Q, Pang B, Dang E, et al. Endothelial dysfunction in psoriasis: an integrative review. J Invest Dermatol. 2024. S0022-202X(24)00171-4. Advance online publication. doi: 10.1016/j.jid.2024.02.013.
   Google Scholar
• Ho AW, Kupper TS. T cells and the skin: from protective immunity to inflammatory skin disorders. Nat Rev Immunol. 2019;19(8):490–502. doi: 10.1038/s41577-019-0162-3.
   PubMed Web of Science ®Google Scholar
• Cheuk S, Wikén M, Blomqvist L, et al. Epidermal Th22 and Tc17 cells form a localized disease memory in clinically healed psoriasis. J Immunol. 2014;192(7):3111–3120.), doi: 10.4049/jimmunol.1302313.
   PubMed Web of Science ®Google Scholar
• Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–1072. doi: 10.1016/j.jaad.2018.11.057.
   PubMed Web of Science ®Google Scholar
• Nast A, Altenburg A, Augustin M, et al. German S3-Guideline on the treatment of psoriasis vulgaris, adapted from EuroGuiDerm - Part 1: Treatment goals and treatment recommendations. J Dtsch Dermatol Ges. 2021;19(6):150–934. doi: 10.1111/ddg.14508.
   Web of Science ®Google Scholar
• Smith CH, Yiu ZZN, Bale T, and British Association of Dermatologists’ Clinical Standards Unit., et al. British association of dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update. Br J Dermatol. 2020;183(4):628–637. doi: 10.1111/bjd.19039.
   PubMed Web of Science ®Google Scholar
• Mehta H, Mashiko S, Angsana J, et al. Differential changes in inflammatory mononuclear phagocyte and T-Cell profiles within psoriatic skin during treatment with Guselkumab vs. Secukinumab. J Invest Dermatol. 2021;141(7):1707–1718.e9. doi: 10.1016/j.jid.2021.01.005.
   PubMed Web of Science ®Google Scholar
• Membrive Jiménez C, Pérez Ramírez C, Sánchez Martín A, et al. Influence of genetic polymorphisms on response to ­biologics in moderate-to-severe psoriasis. J Pers Med. 2021;11(4):293. doi: 10.3390/jpm11040293.
   PubMed Web of Science ®Google Scholar
• Augustin M, Sator PG, von Kiedrowski R, and SERENA study group., et al. Secukinumab demonstrated sustained retention, effectiveness and safety in a real-world setting in patients with moderate-to-severe plaque psoriasis: long-term results from an interim analysis of the SERENA study. J Eur Acad Dermatol Venereol. 2022;36(10):1796–1804. doi: 10.1111/jdv.18329.
   PubMed Web of Science ®Google Scholar
• Yiu ZZN, Mason KJ, Hampton PJ, and BADBIR Study Group., et al. Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the british association of dermatologists biologics and immunomodulators register (BADBIR). Br J Dermatol. 2020;183(2):294–302. doi: 10.1111/bjd.18981.
   PubMed Web of Science ®Google Scholar
• Yiu ZZN, Becher G, Kirby B, and BADBIR Study Group., et al. Drug survival associated with effectiveness and safety of treatment with Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in patients with psoriasis. JAMA Dermatol. 2022;158(10):1131–1141. doi: 10.1001/jamadermatol.2022.2909.
   PubMed Web of Science ®Google Scholar
• Reich K, Armstrong AW, Langley RG, et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet. 2019;394(10201):831–839. doi: 10.1016/S0140-6736(19)31773-8.
   PubMed Web of Science ®Google Scholar
• Reich K, Gordon KB, Strober BE, et al. Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with Guselkumab: results from VOYAGE 1 and VOYAGE 2. Br J Dermatol. 2021;185(6):1146–1159. doi: 10.1111/bjd.20568.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Armstrong AW, Foley P, et al. Guselkumab efficacy after withdrawal is associated with suppression of serum IL-23-Regulated IL-17 and IL-22 in psoriasis: VOYAGE 2 study. J Invest Dermatol. 2019;139(12):2437–2446.e1. doi: 10.1016/j.jid.2019.05.016.
   PubMed Web of Science ®Google Scholar
• Rivera R, Martorell A, López A, et al. Maintenance of response following discontinuation of Guselkumab and Secukinumab in spanish patients who participated in the ECLIPSE study. J Eur Acad Dermatol Venereol. 2021;35(1):e65–e67. doi: 10.1111/jdv.16809.
   PubMed Web of Science ®Google Scholar
• Menter A, Cordoro KM, Davis DMR, et al. Joint American academy of Dermatology-National psoriasis foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. J Am Acad Dermatol. 2020;82(1):161–201. doi: 10.1016/j.jaad.2019.08.049.
   PubMed Web of Science ®Google Scholar
• Peris K, Fortina AB, Bianchi L, et al. Update on the management of pediatric psoriasis: an italian consensus. Dermatol Ther (Heidelb). 2022;12(8):1753–1775. doi: 10.1007/s13555-022-00758-2.
   PubMed Web of Science ®Google Scholar
• Kim J, Bissonnette R, Lee J, et al. The spectrum of mild to severe psoriasis vulgaris is defined by a common activation of IL-17 pathway genes, but with key differences in immune regulatory genes. J Invest Dermatol. 2016;136(11):2173–2182. doi: 10.1016/j.jid.2016.04.032.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Merola JF, Cirulli J, et al. Characteristics of patients with psoriasis treated with apremilast in the corrona psoriasis registry. Dermatol Ther (Heidelb). 2021;11(1):253–263. doi: 10.1007/s13555-020-00479-4.
   PubMed Web of Science ®Google Scholar
• Boehncke WH, Brembilla NC. Unmet needs in the field of psoriasis: pathogenesis and treatment. Clin Rev Allergy Immunol. 2018;55(3):295–311. doi: 10.1007/s12016-017-8634-3.
   PubMed Web of Science ®Google Scholar
• de Hooge M, Ishchenko A, De Craemer AS, et al. Extent of axial damage in psoriatic arthritis and spondyloarthritis: comparative data from the BEPAS and (be-)GIANT multicentre cohorts. RMD Open. 2023;9(2):e002994. doi: 10.1136/rmdopen-2023-002994.
   PubMed Web of Science ®Google Scholar
• Patel HA, Revankar RR, Pedroza ST, et al. The genetic susceptibility to psoriasis and the relationship of linked genes to our treatment options. Int J Mol Sci. 2023;24(15):12310. doi: 10.3390/ijms241512310.
   PubMed Web of Science ®Google Scholar
• Giang NH, Lien NTK, Trang DT, et al. Associations of A20, CYLD, cezanne and JAK2 genes and immunophenotype with psoriasis susceptibility. Medicina (Kaunas). 2023;59(10):1766. doi: 10.3390/medicina59101766.
   PubMed Web of Science ®Google Scholar
• Zhu D, Yao S, Wu H, et al. A transcriptome-wide association study identifies novel susceptibility genes for psoriasis. Hum Mol Genet. 2021;31(2):300–308. doi: 10.1093/hmg/ddab237.
   PubMed Web of Science ®Google Scholar
• Bhatti ZU, Salek MS, Finlay AY. Major life changing decisions and cumulative life course impairment. J Eur Acad Dermatol Venereol. 2011;25(2):245–246; author reply 246. doi: 10.1111/j.1468-3083.2010.03930.x.
   PubMedGoogle Scholar
• Kaeley GS, Eder L, Aydin SZ, et al. Nail psoriasis: diagnosis, assessment, treatment options, and unmet clinical needs. J Rheumatol. 2021;48(8):1208–1220. doi: 10.3899/jrheum.201471.
   PubMed Web of Science ®Google Scholar
• Hjuler KF, Iversen L, Rasmussen MK, et al. Localization of treatment-resistant areas in patients with psoriasis on biologics. Br J Dermatol. 2019;181(2):332–337. doi: 10.1111/bjd.17689.
   PubMed Web of Science ®Google Scholar
• Piaserico S, Riedl E, Pavlovsky L, et al. Comparative effectiveness of biologics for patients with moderate-to-severe psoriasis and special area involvement: week 12 results from the observational psoriasis study of health outcomes (PSoHO). Front Med (Lausanne). 2023;10:1185523. doi: 10.3389/fmed.2023.1185523.
   PubMed Web of Science ®Google Scholar
• Egeberg A, Kristensen LE, Vender R, et al. Sustained resolution of nail psoriasis through 5 years with ixekizumab: a Post-Hoc analysis from UNCOVER-3. Acta Derm Venereol. 2022;102:adv00787. doi: 10.2340/actadv.v102.2269.
   PubMed Web of Science ®Google Scholar
• Egeberg A, Kristensen LE, Puig L, et al. Network meta-analyses comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis at 24-28 and 48-52 weeks. J Dermatolog Treat. 2023;34(1):2263108. doi: 10.1080/09546634.2023.2263108.
   PubMed Web of Science ®Google Scholar
• Karmacharya P, Wright K, Achenbach SJ, et al. Diagnostic delay in psoriatic arthritis: a population-based study. J Rheumatol. 2021;48(9):1410–1416. doi: 10.3899/jrheum.201199.
   PubMed Web of Science ®Google Scholar
• Haroon M, Gallagher P, FitzGerald O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann Rheum Dis. 2015;74(6):1045–1050. doi: 10.1136/annrheumdis-2013-204858.
   PubMed Web of Science ®Google Scholar
• Simopoulou T, Tsiogkas SG, Zafiriou E, et al. Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis. Drugs Today (Barc). 2023;59(3):135–167. doi: 10.1358/dot.2023.59.3.3419557.
   PubMed Web of Science ®Google Scholar
• Alegre-Sancho JJ, Núñez-Monje V, Campos-Fernández C, et al. Real-world effectiveness and persistence of secukinumab in the treatment of patients with psoriatic arthritis. Front Med (Lausanne). 2023;10:1294247. doi: 10.3389/fmed.2023.1294247.
   PubMed Web of Science ®Google Scholar
• Strober B, Gooderham M, de Jong EMGJ, et al. Depressive symptoms, depression, and the effect of biologic therapy among patients in psoriasis longitudinal assessment and registry (PSOLAR). J Am Acad Dermatol. 2018;78(1):70–80. doi: 10.1016/j.jaad.2017.08.051.
   PubMed Web of Science ®Google Scholar
• Rosenthal YS, Schwartz N, Sagy I, et al. Incidence of psoriatic arthritis among patients receiving biologic treatments for psoriasis: a nested Case-Control study. Arthritis Rheumatol. 2022;74(2):237–243. doi: 10.1002/art.41946.
   PubMed Web of Science ®Google Scholar
• Gisondi P, Bellinato F, Targher G, et al. Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis. Ann Rheum Dis. 2022;81(1):68–73. doi: 10.1136/annrheumdis-2021-219961.
   PubMed Web of Science ®Google Scholar
• Zabotti A, Giovannini I, McGonagle D, et al. Arthritis interception in patients with psoriasis treated with Guselkumab. Dermatol Ther (Heidelb). 2022;12(1):5–8. doi: 10.1007/s13555-021-00650-5.
   PubMed Web of Science ®Google Scholar
• Savage L, Goodfield M, Horton L, et al. Regression of peripheral subclinical enthesopathy in therapy-Naive patients treated with ustekinumab for moderate-to-severe chronic plaque psoriasis: a Fifty-Two-week, prospective, Open-Label feasibility study. Arthritis Rheumatol. 2019;71(4):626–631. doi: 10.1002/art.40778.
   PubMed Web of Science ®Google Scholar